18+ · Research Use Only · Not for Human Consumption
Retatrutide Phase 3: the TRIUMPH timeline.
The triple agonist posted the strongest Phase 2 weight number in the incretin class. Here is where the Phase 3 program stands in 2026 and what its outcome would change.
The Phase 2 result that set the bar
Retatrutide is a single molecule that agonizes three receptors: GLP-1, GIP and glucagon. The GLP-1 and GIP arms follow the template that tirzepatide established. The glucagon arm is the addition, studied for its effect on energy expenditure rather than appetite alone. That third mechanism is the whole argument for the compound.
The Phase 2 data, published by Jastreboff et al. in NEJM in 2023, reported a 24.2% mean weight reduction at 48 weeks at the highest dose. For context, tirzepatide reached 22.5% at 72 weeks in SURMOUNT-1 and semaglutide reached 14.9% at 68 weeks in STEP 1. Retatrutide got further, faster, in a smaller trial. Phase 2 numbers are not Phase 3 numbers, and everyone in the field knows compounds can lose ground when the sample size grows. But 24.2% was enough to make TRIUMPH the most watched obesity program in development.
Where TRIUMPH stands in 2026
TRIUMPH is Eli Lilly's Phase 3 program for retatrutide, and as of 2026 it is ongoing. Phase 3 obesity trials run long by design: they enroll thousands of participants and follow them well past a year to establish durability and safety at scale. That structure means results arrive in stages rather than as one announcement, with individual studies reading out as they complete.
No final TRIUMPH readouts have been published as of this writing, and any specific date you see quoted on forums is speculation. The honest position is this: the program is active, the Phase 2 result is the benchmark it has to defend, and until Lilly publishes, nobody outside the trial knows the number. When results do land, expect them in a major journal with heavy coverage, the same path SURMOUNT-1 and STEP 1 took.
What approval would mean for the research market
If TRIUMPH succeeds and regulators approve retatrutide, the pharmaceutical version will arrive as a branded injectable at branded prices, and Philippine availability will lag Western launches the way it did for tirzepatide. Approval also tends to raise, not lower, interest in the research-grade market, because published Phase 3 data gives researchers a much richer literature to work against.
Today, before any approval, retatrutide exists in the Philippines only as a research chemical. Retatrutide 10mg vials are stocked in Metro Manila cold storage at ₱2,790, or ₱2,510 on a first order, with same-day dispatch on verified orders placed before noon. Every vial carries a printed batch number. The full local picture is in the retatrutide price guide.
Supplied for laboratory research use only. Not for human consumption. Nothing on this page is medical advice.
Retatrutide Phase 3 questions
What did retatrutide show in Phase 2?
In the Phase 2 trial published by Jastreboff et al. in NEJM 2023, retatrutide produced a 24.2% mean weight reduction at 48 weeks, the largest figure reported for any incretin-class compound at that stage of development.
Is retatrutide approved anywhere yet?
No. As of 2026 retatrutide remains an investigational compound. The Phase 3 TRIUMPH program is ongoing and no regulator has granted approval. Until that changes, it exists only as a trial drug and as a research chemical.
Can I get retatrutide in the Philippines now?
Not from any pharmacy. Research-grade 10mg vials are stocked locally by Primara Labs at ₱2,790, or ₱2,510 on a first order, supplied strictly for laboratory research use.
How does retatrutide differ from tirzepatide?
Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds a third target, the glucagon receptor, which is the mechanistic reason researchers watch whether its Phase 2 lead holds up in Phase 3.